Equities

BRAIN Biotech AG

BRAIN Biotech AG

Actions
  • Price (EUR)2.90
  • Today's Change0.20 / 7.41%
  • Shares traded200.00
  • 1 Year change-27.68%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments5.418.8125
Total Receivables, Net9.83116.95
Total Inventory9.769.667.02
Prepaid expenses0.390.330.32
Other current assets, total0.090.240.18
Total current assets253039
Property, plant & equipment, net292924
Goodwill, net6.676.614.73
Intangibles, net8.55108.81
Long term investments1.461.940.55
Note receivable - long term0.050.100.15
Other long term assets00.010.02
Total assets717878
LIABILITIES
Accounts payable5.626.753.83
Accrued expenses3.002.231.92
Notes payable/short-term debt000
Current portion long-term debt/capital leases3.702.712.32
Other current liabilities, total5.179.703.27
Total current liabilities172111
Total long term debt188.039.06
Total debt211111
Deferred income tax3.773.292.79
Minority interest1.244.613.04
Other liabilities, total8.881113
Total liabilities494839
SHAREHOLDERS EQUITY
Common stock222222
Additional paid-in capital939396
Retained earnings (accumulated deficit)(94)(85)(80)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.630.330.56
Total equity223039
Total liabilities & shareholders' equity717878
Total common shares outstanding222222
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.